BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRODELVY (sacituzumab govitecan) is an antibody-drug conjugate (ADC) that combines an anti-Trop-2 monoclonal antibody with the topoisomerase I inhibitor SN-38. It is approved for metastatic triple-negative breast cancer and other solid tumors where Trop-2 expression is present. The drug works by binding to Trop-2 on cancer cells and delivering cytotoxic payload intracellularly.
$5MPart D
PeakTRODELVY is in peak lifecycle stage with modest Part D adoption, suggesting the commercial team is scaling beyond launch phase but faces opportunities for expanded market penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Started Jun 2026
765 enrolled
Breast CancerTriple-negative Breast Cancer
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Started Jun 2026
35 enrolled
Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
Started Oct 2025
12 enrolled
Stage IV (Metastatic) Breast Cancer
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Started Sep 2025
31 enrolled
Metastatic Triple-Negative Breast Cancer
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Started Jul 2025
40 enrolled
Squamous Cell Carcinoma of Head and NeckSinus CancerNasal Cavity Cancer+9 more
Worked on TRODELVY at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.